@article{oai:repo.qst.go.jp:00047492,
 author = {Kimura, Yasuyuki and Seki, Chie and Ikoma, Yoko and Ichise, Masanori and Kawamura, Kazunori and Takahata, Keisuke and Moriguchi, Sho and Nagashima, Tomohisa and Ishii, Tatsuya and Kitamura, Soichiro and Niwa, Fumitoshi and Endo, Hironobu and Yamada, Makiko and Higuchi, Makoto and Zhang, Ming-Rong and Suhara, Tetsuya and 木村 泰之 and 関 千江 and 生駒 洋子 and 市瀬 正則 and 河村 和紀 and 高畑 圭輔 and 森口 翔 and 永嶌 朋久 and 石井 辰弥 and 北村 聡一郎 and 丹羽 文俊 and 遠藤 浩信 and 山田 真希子 and 樋口 真人 and 張 明栄 and 須原 哲也},
 issue = {9},
 journal = {European journal of nuclear medicine and molecular imaging},
 month = {Feb},
 note = {The histamine H3 receptors are presynaptic neuroreceptors that inhibit the release of histamine and other neurotransmitters. The receptors are considered a drug target for sleep disorders and neuropsychiatric disorders with cognitive decline. We developed a novel PET ligand for the H3 receptors, [(11)C]TASP0410457 ([(11)C]TASP457), with high affinity, selectivity and favorable kinetic properties in the monkey, and evaluated its kinetics and radiation safety profile for quantifying the H3 receptors in human brain.},
 pages = {1653--1663},
 title = {[(11)C]TASP457, a novel PET ligand for histamine H3 receptors in human brain.},
 volume = {43},
 year = {2016}
}